World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02203266
Date of registration: 27/07/2014
Prospective Registration: No
Primary sponsor: Beaumont Hospital
Public title: Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting
Scientific title: A Randomised, Parallel-group, Multi-centre Trial Using a Novel INCA Tracker Device to Measure and Monitor Compliance and Technique of Seretide Diskus Inhaler in a Community Pharmacy Setting
Date of first enrolment: February 2014
Target sample size: 152
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02203266
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
Ireland
Contacts
Name:     Richard Costello, Professor
Address: 
Telephone:
Email:
Affiliation:  Royal College of Surgeons in Ireland, Clinical Research Centre, Beaumont Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

- Must be 18 years old or above

- Capable of understanding and willing to provide voluntary informed consent before any
protocol specific procedures are performed

- Capable of understanding and complying with the requirements of the protocol, and
demonstrating a willingness to attend for all required visits.

- Able and willing to take inhaled medication.

- Have a valid prescription for use of a Seretide diskus inhaler or already using a
Seretide diskus inhaler.

- Have a history of regular attendance in the pharmacy in which they are recruited which
will be demonstrated by the subject having collected three prescriptions for any
medication in that pharmacy in the six months preceeding their recruitment to the
study.

Exclusion Criteria:

- Patient expressly reports that their physician has indicated that they will not be
continuing to receive Seretide over the next 6 months



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Asthma
Pulmonary Disease, Chronic Obstructive
Intervention(s)
Behavioral: Education
Device: Feedback
Primary Outcome(s)
Rate of adherence [Time Frame: 2 months and 6 months]
Secondary Outcome(s)
Rescue antibiotic and/or steroid medication use [Time Frame: 6 months]
Technique adherence [Time Frame: Two months and six months]
Quality of life [Time Frame: 2 months and 6 months]
Adherence in the time domain [Time Frame: Two months and six months]
Rescue inhaled medication use [Time Frame: Six months]
Secondary ID(s)
RC004
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Royal College of Surgeons, Ireland
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history